Analysts Offer Insights on Healthcare Companies: Flex Pharma (NASDAQ: FLKS), Pacira Pharmaceuticals (NASDAQ: PCRX) and Anthem (NYSE: ANTM)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Flex Pharma (NASDAQ: FLKS), Pacira Pharmaceuticals (NASDAQ: PCRX) and Anthem (NYSE: ANTM).

Flex Pharma (NASDAQ: FLKS)

In a report released today, Joshua Schimmer from Piper Jaffray reiterated a Buy rating on Flex Pharma (NASDAQ: FLKS), with a price target of $15. The company’s shares opened today at $4.93, close to its 52-week low of $4.55.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -12.0% and a 29.1% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Voyager Therapeutics Inc.

Flex Pharma has an analyst consensus of Strong Buy.

Pacira Pharmaceuticals (NASDAQ: PCRX)

In a report released today, Boris Peaker from Cowen & Co. reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX). The company’s shares opened today at $33.35, close to its 52-week low of $30.60.

Peaker said:

“This morning Pacira reported 3Q16 earnings.”

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 7.8% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $64, representing a 91.9% upside.

In a report issued on October 26, BMO Capital also upgraded the stock to Hold with a $35 price target.
Anthem (NYSE: ANTM)

Cantor Fitzgerald analyst Joseph France reiterated a Hold rating on Anthem (NYSE: ANTM) today and set a price target of $125. The company’s shares opened today at $122.99.

France wrote:

“Essentially in-line 3Q16, but cautious outlook. ANTM reported essentially in-line revenue and earnings but continues to lose money on the exchanges. Medicaid margins (especially in Iowa) are under pressure from higher-than- expected utilization and possibly unsound rates in Iowa. Other commercial insurers have also been adversely selected, and we believe that ANTM’s target margins of 3-5% in 2018 are optimistic, relative to the profitability of Medicare Advantage and Medicaid managed care as well as recent trends in ACA plans. Guidance unchanged. ANTM slightly lowered its full year EPS outlook from at least $10.80 to $10.80 because of mid-single-digit margin losses in ACA- compliant plans (1.4 million lives) and high utilization in Iowa, a new market, earlier this year.”

According to TipRanks.com, France is a 3-star analyst with an average return of 0.6% and a 38.2% success rate. France covers the Healthcare sector, focusing on stocks such as WellCare Health Plans, Envision Healthcare, and Acadia Healthcare.

Anthem has an analyst consensus of Moderate Buy, with a price target consensus of $144.33.